Core Viewpoint - Cogent Biosciences, Inc. has announced a public offering of 22,222,223 shares of common stock at a price of $9.00 per share, aiming to raise approximately $200 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 3,333,333 shares on the same terms [1]. - The expected closing date for the offering is around July 10, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the development, regulatory, and commercial preparation activities related to bezuclastinib and other product candidates [2]. - Funds will also support the planned commercial launch of bezuclastinib, along with working capital and general corporate purposes [2]. Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with bezuclastinib being the most advanced clinical program [5]. - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is associated with systemic mastocytosis and advanced gastrointestinal stromal tumors [5]. - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [5].

Core Viewpoint - ZyVersa Therapeutics, Inc. has entered into a warrant inducement agreement with an institutional investor, which includes the immediate exercise of existing warrants and the issuance of new warrants at a reduced exercise price of $0.67, generating approximately $2.0 million in gross cash proceeds for working capital and corporate purposes [1][2]. Group 1 - The agreement involves the immediate exercise of Series A-2 Warrants for up to 957,200 shares and Series A-3 Warrants for up to 2,105,265 shares at an exercise price of $0.67 [1]. - The investor will receive new Series A-4 Warrants to purchase up to 6,124,930 shares, which will be exercisable upon stockholder approval and will expire five years from that date [2]. - The transaction is expected to close on or about July 9, 2025, pending customary closing conditions [2]. Group 2 - A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction [3]. - The new warrants were offered in a private placement under an exemption from the registration requirements of the Securities Act, and the company plans to file a registration statement with the SEC for the resale of common stock upon exercise of the new warrants [4]. Group 3 - ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases, utilizing proprietary technologies such as Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100 [6].

China Healthcare | Asia Pacific Weekly Rx Express 2025.07.04 July 4, 2025 01:46 PM GMT Sino Biopharma obtained approval for recombinant human coagulation factor VIIa N01: The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above, with factor VII or IX inhibitors >5 Bethesda units (BU). (Company filing, July 4, 2025) Hengrui obtained approval for an additional indication for JAK1 inhibitor (ivarmacitinib): Ivarmacitinib is China's first domestically-deve ...

Tonner Drones Provides H1 2025 Business Update and Strategic Outlook Including Treasury Expansion into Crypto Sector Paris, July 3, 2025 at 18:30, Tonner Drones (the “Company”) is pleased to provide an update on H1 where many things were developing positively for the company. In H2, Tonner Drones will further decide on its business strategy, while exploring emerging opportunities in the crypto sector to enhance shareholder value. Financial debt reduced by €1,4M from €5,5M to €4,1M.Cash and cash equivalents ...

Core Insights - Esperion has appointed Craig Thompson, CEO of Cerevance, as an independent director on its Board of Directors, expanding the board to eight members [1][2]. Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing and marketing innovative medicines for cardiovascular disease, specifically targeting patients with elevated low-density lipoprotein cholesterol (LDL-C) [7]. - The company has developed the only FDA-approved oral, once-daily, non-statin medications for at-risk cardiovascular patients, supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial [7]. Leadership Experience - Craig Thompson brings over 20 years of biopharmaceutical leadership experience, with a strong background in pharmaceutical commercialization and clinical development, which aligns with Esperion's mission [2][3]. - Prior to joining Esperion, Mr. Thompson held leadership roles at various biotechnology companies, including Cerevance, Neurana Pharmaceuticals, and Anthera Pharmaceuticals, and has experience in global marketing at Pfizer and Merck [4][5][6]. Strategic Focus - The appointment of Mr. Thompson is expected to enhance Esperion's strategic insight and operational expertise as the company aims to expand its impact in cardiovascular and cardiometabolic drug development [2][3]. - Esperion is advancing its pre-clinical pipeline and focusing on developing ATP citrate lyase inhibitors (ACLYi), which are expected to enable rational drug design and the development of highly potent inhibitors [7][8].

Summary of Whitehawk Therapeutics Fireside Chat - June 26, 2025 Company Overview - Whitehawk Therapeutics, formerly known as Adi Bioscience, underwent a transformation completed in Q1 2025, focusing on developing an advanced ADC (antibody-drug conjugate) portfolio after selling its mTOR inhibitor product to Kaken Pharmaceuticals for $100 million [3][4][15]. Pipeline and Technology - The company is developing a three-asset ADC portfolio targeting various cancers, including lung, ovarian, and gastrointestinal cancers, with a focus on established tumor biology and clinically validated tumor markers [4][5][14]. - All three programs are currently in preclinical stages, with IND (Investigational New Drug) filings anticipated by mid-2026 [6][13]. - The ADC platform utilizes a linker payload technology designed for greater stability, reduced off-target toxicity, and improved therapeutic index [5][12][13]. Key Programs 1. **HAWK 007 (PTK7-targeted ADC)** - PTK7 is broadly overexpressed in various solid tumors, with expression rates of 60-70% in cancer patients [20][21]. - The program aims to demonstrate differentiation from previous compounds, with a focus on lung cancer, ovarian cancer, and triple-negative breast cancer [24][26]. - Initial phase one trials will target patients with moderate to high expression of PTK7, aiming for a minimum response rate of 40% in lung cancer and 50% in ovarian cancer [56]. 2. **HAWK 016 (MUC16-targeted ADC)** - MUC16 is a circulating biomarker in ovarian cancer, with the approach focusing on targeting the membrane-bound portion to avoid complications from circulating biomarkers [60][63]. - The program will initially focus on gynecological cancers, with potential expansion into pancreatic and non-small cell lung cancers in the future [70]. 3. **HAWK 206 (SEZ6-targeted ADC)** - This program is in the early stages, with a biparatopic approach aimed at enhancing internalization and efficacy in neuroendocrine tumors and small cell lung cancer [71][78]. Competitive Landscape - The ADC market is competitive, with other companies like Zymeworks and Day One Pharmaceuticals developing next-generation ADCs. Whitehawk believes its platform offers superior optimization in terms of linker stability, hydrophilicity, and therapeutic index [36][46]. - The company aims to differentiate its products by demonstrating better efficacy and safety profiles compared to existing therapies [30][46]. Financial Position and Future Outlook - Whitehawk started Q2 2025 with approximately $185 million in cash, providing operational runway into early 2028 to generate clinical data before seeking additional funding [88][90]. - The company plans to release more preclinical data in 2026, focusing on a comprehensive view of its products' potential before public disclosures [89][90]. Conclusion - Whitehawk Therapeutics is positioned to make significant advancements in the ADC space with its innovative platform and targeted therapies. The upcoming IND filings and clinical trials will be critical in validating its approach and establishing its market presence.

BeiGene (BGNE) Update / Briefing June 26, 2025 08:30 AM ET Speaker0 Hello, everyone. Welcome to b one medicine's twenty twenty five investor research and development day. My name is Liza Heaps. I'm senior director of investor relations at b one. We are very excited to host our investor event today, both in person in New York City and online for our global attendees. Thank you all very much for joining us. This is truly an exciting time at b one, and we are thrilled to walk you through recent progress to dat ...

Company Overview - ZyVersa Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [5] - The company is advancing a therapeutic development pipeline that includes Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases [5] Share Purchase Agreement (SPA) - ZyVersa has entered into a share purchase agreement with Williamsburg Venture Holdings, allowing the company to sell up to $10 million worth of common stock over a 24-month period [3] - The SPA provides ZyVersa with flexibility in planning the timing and amount of equity sales, aiming to minimize dilution while sustaining shareholder value [2][3] - ZyVersa retains control over the timing and amount of all common stock sales, with no associated warrants or derivatives [3] Market Potential - The global drug market for kidney diseases was valued at $18 billion in 2024 and is projected to reach $30 billion by 2034 [1]

Core Insights - Arbutus Biopharma Corporation has reacquired the rights to its lead compound, imdusiran, from Qilu Pharmaceutical, concluding their strategic partnership for the development and commercialization of imdusiran in Greater China [1][2] - The decision to terminate the partnership was influenced by Qilu's pipeline reprioritization and Arbutus' focus on advancing its pipeline efficiently [2] - Imdusiran has shown promising results, achieving functional cure in eight patients during Phase 2a trials [2][3] Company Overview - Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B virus (cHBV) [7] - The company is also developing an oral PD-1 inhibitor (AB-101) for cHBV treatment and is involved in legal actions to protect its intellectual property related to its patented LNP technology [7] Product Details - Imdusiran is designed to reduce all HBV viral proteins and antigens, which is essential for reawakening the immune system to control the virus [5] - The treatment has been reported to be generally safe and well-tolerated, with significant reductions in hepatitis B surface antigen (HBsAg) and HBV DNA [5] Scientific Advisory Board - Arbutus has established a new Scientific Advisory Board consisting of experts in chronic hepatitis B treatment to guide its strategic evaluation of the cHBV pipeline [2]

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “Consolidation”) will be June 24, 2025. As outlined in the Company’s news release dated May 15, 2025, the Consolidation will be conducted on the basis of one (1) post-consolidation common share (“Post-Consolidation Share”) for every ten (10) pre-consolidation common s ...